로사르탄 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측(2018-2028년) : 공급원별, 형태별, 용도별, 지역별, 경쟁

The Global Losartan Market, valued at USD 1.64 Billion in 2022, is poised for remarkable growth in the forecast period, with an anticipated Compound Annual Growth Rate (CAGR) of 4.89% through 2028.

Losartan is a medication primarily prescribed for the treatment of high blood pressure (hypertension) and specific heart conditions. It falls under the category of drugs known as angiotensin II receptor blockers (ARBs). Losartan operates by relaxing blood vessels, effectively reducing blood pressure and enhancing blood circulation.

The pharmaceutical market for Losartan encompasses the production, distribution, and sale of Losartan tablets or capsules by pharmaceutical companies. Additionally, this market may include various generic versions of Losartan that become available as the patent for the brand-name medication expires. Losartan is not only used to manage hypertension but may also be employed for treating conditions like heart failure and reducing the risk of stroke in individuals with hypertension and an enlarged heart.

Key Market Drivers

Growing Prevalence of Hypertension

High blood pressure (hypertension) is a common health condition worldwide. As the global population ages and lifestyle factors such as poor diet and sedentary behavior continue, the prevalence of hypertension tends to increase. This drives the demand for antihypertensive medications like Losartan. Modern sedentary lifestyles, coupled with diets high in salt and processed foods, contribute to rising blood pressure levels. Poor dietary choices, lack of exercise, and obesity are known risk factors for hypertension. As these lifestyle habits persist, more people are diagnosed with high blood pressure, leading to an increased demand for medications like Losartan to control and manage their condition.

Increased awareness and healthcare accessibility have led to earlier diagnosis and treatment of hypertension. Health campaigns and routine health check-ups have heightened awareness of the risks associated with uncontrolled blood pressure, prompting individuals to seek medical intervention. Losartan's efficacy in reducing blood pressure and its tolerability have made it a preferred choice among healthcare providers, further driving its demand. The availability of generic versions of Losartan has made hypertension management more affordable for patients, increasing its accessibility to a broader population. This affordability factor has a significant impact on the demand for Losartan, especially in regions with limited healthcare resources.

Rising Geriatric Population

The rising geriatric population is a significant driver of the increasing demand for Losartan, a medication used to manage hypertension and certain heart conditions. This demographic shift is reshaping healthcare priorities and intensifying the need for effective treatments for age-related health issues, such as high blood pressure. As individuals age, the risk of developing hypertension rises substantially. Blood pressure tends to increase with age due to changes in blood vessel elasticity and hormonal regulation. Consequently, a growing elderly population translates to a higher prevalence of hypertension, necessitating pharmaceutical interventions like Losartan to maintain optimal blood pressure levels.

Losartan is particularly well-suited for older adults. Its mechanism of action as an angiotensin II receptor blocker (ARB) allows it to relax blood vessels, reduce arterial stiffness, and lower blood pressure effectively, all of which are crucial in managing hypertension in the elderly. Additionally, Losartan's safety profile and relatively mild side effects make it a preferred choice for older individuals who may have multiple medications to manage various age-related conditions.

Improved healthcare access and increased awareness of the health risks associated with uncontrolled hypertension have led to earlier diagnosis and treatment in the elderly population. With healthcare providers emphasizing the importance of blood pressure control, Losartan has become a staple in the medical management of hypertension among older adults. The aging population trend is expected to continue in the coming years, with a growing proportion of people over the age of 65. Consequently, the demand for Losartan and other antihypertensive medications is poised to rise as healthcare systems address the unique healthcare needs of this demographic. Losartan's role in maintaining cardiovascular health and quality of life in the elderly population underscores its significance in meeting the healthcare demands of an aging world.

Increasing Clinical Efficacy

Losartan and other angiotensin II receptor blockers (ARBs) have demonstrated their effectiveness in lowering blood pressure and reducing the risk of cardiovascular events. Positive clinical outcomes and a good safety profile can drive healthcare providers to prescribe Losartan. The increasing clinical efficacy of Losartan is a key driver behind its growing demand in the healthcare sector. Losartan, an angiotensin II receptor blocker (ARB), has gained prominence due to its effectiveness in managing hypertension and certain heart conditions, making it a preferred choice for both healthcare providers and patients.

Furthermore, Losartan has shown efficacy in reducing the risk of cardiovascular events in hypertensive individuals. It is known to have a positive impact on cardiac health by decreasing the strain on the heart and improving blood flow. Its protective effects on the cardiovascular system make it a valuable tool in the prevention of heart attacks, strokes, and other cardiovascular complications, which is a critical consideration for healthcare providers and patients alike. The increasing clinical efficacy of Losartan in lowering blood pressure, reducing cardiovascular risks, and its favorable tolerability profile have made it a preferred choice for healthcare providers and patients. This clinical success is a driving force behind the growing demand for Losartan in the treatment of hypertension and related cardiovascular conditions.

Patent Expiration and Generic Competition

The expiration of patents for brand-name Losartan medications allows generic versions to enter the market. Generic competition often leads to lower drug prices, making the medication more accessible to a broader population. The expiration of patents for brand-name medications like Losartan has led to the introduction of generic versions, significantly increasing the demand for Losartan. Generic medications are typically more affordable than their brand-name counterparts. As Losartan's patent expired, generic manufacturers were able to produce and market their versions of the drug at a lower cost. This affordability makes Losartan accessible to a broader population of patients, increasing its demand among those who may have been previously deterred by the cost of the brand-name product.

With the availability of generic Losartan, more healthcare providers may be inclined to prescribe it as a cost-effective option for their patients. This expanded access to Losartan enables a larger number of individuals to benefit from its antihypertensive properties, thus increasing demand. As generic Losartan becomes more prevalent and trusted in the market, patients and healthcare professionals alike become more aware of its availability and efficacy. This increased awareness leads to more prescriptions and higher demand for Losartan.

Key Market Challenges

Side Effects and Tolerability

The side effects and tolerability of Losartan can be a significant factor hindering its demand and use among some individuals. While Losartan is generally well-tolerated by many patients, some may experience side effects that lead to discontinuation or reluctance to use the medication. Tolerability also varies from person to person. Some patients may find Losartan to be better tolerated than other antihypertensive medications, while others may have a different response. Individual factors, such as age, underlying medical conditions, and concomitant medications, can influence how well a person tolerates Losartan. While Losartan is an effective antihypertensive medication, its side effects and tolerability issues can hinder its demand and use among certain individuals. Patient education, open communication with healthcare providers, and personalized treatment plans are essential in addressing these concerns and ensuring that patients receive appropriate treatment for their hypertension while minimizing side effects.

Alternative Medications

There are several classes of antihypertensive medications available, and healthcare providers may prescribe alternative drugs based on individual patient characteristics and preferences. Factors such as comorbidities, contraindications, and patient response can influence the choice of medication, potentially reducing the demand for Losartan in some cases. Patient preferences and beliefs about medications can influence their willingness to take Losartan or other drugs. Some patients may prefer natural remedies, holistic approaches, or alternative therapies over pharmaceutical interventions, reducing the demand for Losartan. Healthcare disparities, including unequal access to healthcare services and medications, can limit the demand for Losartan among underserved populations. Inequities in healthcare access can prevent individuals from receiving appropriate diagnoses and treatments.

Patients with specific medical conditions or contraindications may not be suitable candidates for Losartan. For instance, individuals with certain kidney conditions or allergies to Losartan may be prescribed alternative medications. In some cases, healthcare providers prescribe combination therapies that include more than one type of antihypertensive medication. These combinations can include different classes of drugs or multiple drugs within the same class. The choice of combination therapy depends on the patient's unique medical needs and the desire for optimal blood pressure control.

Key Market Trends

Telehealth and Remote Monitoring

The adoption of telehealth and remote monitoring technologies has expanded access to healthcare services. These technologies allow healthcare providers to monitor patients' blood pressure remotely and adjust treatment plans as needed, potentially increasing the demand for medications like Losartan. Telehealth allows patients to consult with healthcare providers remotely, eliminating geographical barriers and making it easier for individuals to receive timely medical care. This enhanced accessibility can lead to more frequent monitoring of blood pressure and better medication management. Patients can discuss their treatment plans, including the use of Losartan, with healthcare professionals from the comfort of their homes.

Remote monitoring devices, such as home blood pressure monitors and wearable devices, enable patients to track their blood pressure levels consistently. These devices can transmit data directly to healthcare providers, allowing for real-time monitoring and adjustments to treatment plans when necessary. Losartan's effectiveness can be assessed more accurately through continuous monitoring.

Personalized Medicine

Advances in healthcare technology and genetic research are leading to more personalized treatment approaches. Tailored treatment plans that consider an individual's genetic makeup and unique health characteristics may increase the demand for medications like Losartan, which can be part of a personalized hypertension management strategy. Personalized medicine often begins with genetic profiling. By analyzing an individual's genetic makeup, healthcare providers can identify genetic variations that influence their response to medications. For Losartan, genetic testing can help determine whether a patient is more likely to respond favorably to the drug or if alternative treatments might be more appropriate. This precise approach ensures that Losartan is prescribed to those who are most likely to benefit from it, increasing demand among suitable candidates.

Personalized medicine allows for the fine-tuning of medication dosages based on genetic and individual patient data. For Losartan, this means that healthcare providers can adjust the dosage to achieve the optimal blood pressure control for each patient. Avoiding overmedication or undermedication enhances patient outcomes and reduces potential side effects, increasing patient satisfaction and demand for Losartan.

Segmental Insights

Form Insights

Based on the form, the market is segmented into tablet and powder. The demand for Losartan in tablet form is higher than that for other forms, such as powder. Tablets are easy to handle and swallow, making them a convenient choice for most patients, including the elderly and those with swallowing difficulties. Tablets are pre-measured and provide a standardized dosage, ensuring accurate and consistent medication administration. Losartan tablets are typically packaged in blister packs or bottles, making it easy to store and transport them safely. Patients and healthcare providers are generally more familiar with tablet medications, which contributes to their popularity.

Application Insights

Based on the application segment, the market is segmented into hypertension, stroke, diabetic nephropathy, and others. The hypertension segment dominated the market as Losartan is primarily used for the treatment of hypertension, which is commonly known as high blood pressure. Hypertension is a widespread health issue, affecting a substantial portion of the global population. It is estimated that over one billion people worldwide have hypertension. This high prevalence ensures a consistent and substantial demand for antihypertensive medications like Losartan. In recent years, there has been a concerted effort to raise awareness about hypertension and promote regular blood pressure monitoring. As a result, more individuals are being diagnosed with high blood pressure, leading to an increased demand for effective treatments. Hypertension tends to become more prevalent with age. As the global population ages, a larger proportion of individuals are at risk of developing hypertension, further driving the demand for antihypertensive medications.

Regional Insights

North America, including the United States and Canada, has a significant demand for antihypertensive medications like Losartan. The region has a large aging population, and hypertension is a common health issue. Increased awareness of cardiovascular health and access to healthcare services contribute to a robust demand for these medications. The United States and Canada have well-established healthcare systems and infrastructure. Access to healthcare services, including regular check-ups and diagnostic testing, is relatively widespread. This facilitates the diagnosis and management of hypertension and contributes to the demand for antihypertensive medications. There is a strong emphasis on health awareness and prevention in North America. Educational campaigns and initiatives by healthcare organizations, government agencies, and non-profit organizations promote awareness of cardiovascular risk factors, including hypertension. This heightened awareness encourages individuals to seek medical care and adhere to prescribed treatment plans, including the use of medications like Losartan.

Key Market Players

• Merck & Co. Inc.

• Pfizer Inc.

• Teva Pharmaceutical Industries Ltd.

• Sanofi S.A.

• Novartis International AG

• Dr. Reddy's Laboratories Ltd.

• Sun Pharmaceuticals Industries Ltd.

• Aurobindo Pharma Ltd.

• Torrent Pharmaceutical Ltd.

• Lupin Ltd.

Report Scope:

In this report, the Global Losartan Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Losartan Market, By Source:

• Contract Manufacturing Organizations
• In-House

Losartan Market, By Form:

• Tablet
• Powder

Losartan Market, By Application:

• Hypertension
• Stroke
• Diabetic Nephropathy
• Others

Losartan Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait
• Turkey
• Egypt

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Losartan Market.

Available Customizations:

• Global Losartan market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Losartan Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Source (Contract Manufacturing Organizations, In-House)
  • 5.2.2. By Form (Tablet, Powder)
  • 5.2.3. By Application (Hypertension, Stroke, Diabetic Nephropathy, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2022)
• 5.3. Market Map

6. North America Losartan Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Source
  • 6.2.2. By Form
  • 6.2.3. By Application
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Losartan Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Source
      • 6.3.1.2.2. By Form
      • 6.3.1.2.3. By Application
  • 6.3.2. Canada Losartan Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Source
      • 6.3.2.2.2. By Form
      • 6.3.2.2.3. By Application
  • 6.3.3. Mexico Losartan Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Source
      • 6.3.3.2.2. By Form
      • 6.3.3.2.3. By Application

7. Europe Losartan Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Source
  • 7.2.2. By Form
  • 7.2.3. By Application
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Losartan Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Source
      • 7.3.1.2.2. By Form
      • 7.3.1.2.3. By Application
  • 7.3.2. United Kingdom Losartan Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Source
      • 7.3.2.2.2. By Form
      • 7.3.2.2.3. By Application
  • 7.3.3. Italy Losartan Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Source
      • 7.3.3.2.2. By Form
      • 7.3.3.2.3. By Application
  • 7.3.4. France Losartan Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Source
      • 7.3.4.2.2. By Form
      • 7.3.4.2.3. By Application
  • 7.3.5. Spain Losartan Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Source
      • 7.3.5.2.2. By Form
      • 7.3.5.2.3. By Application

8. Asia-Pacific Losartan Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Source
  • 8.2.2. By Form
  • 8.2.3. By Application
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Losartan Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Source
      • 8.3.1.2.2. By Form
      • 8.3.1.2.3. By Application
  • 8.3.2. India Losartan Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Source
      • 8.3.2.2.2. By Form
      • 8.3.2.2.3. By Application
  • 8.3.3. Japan Losartan Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Source
      • 8.3.3.2.2. By Form
      • 8.3.3.2.3. By Application
  • 8.3.4. South Korea Losartan Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Source
      • 8.3.4.2.2. By Form
      • 8.3.4.2.3. By Application
  • 8.3.5. Australia Losartan Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Source
      • 8.3.5.2.2. By Form
      • 8.3.5.2.3. By Application

9. South America Losartan Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Source
  • 9.2.2. By Form
  • 9.2.3. By Application
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Losartan Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Source
      • 9.3.1.2.2. By Form
      • 9.3.1.2.3. By Application
  • 9.3.2. Argentina Losartan Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Source
      • 9.3.2.2.2. By Form
      • 9.3.2.2.3. By Application
  • 9.3.3. Colombia Losartan Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Source
      • 9.3.3.2.2. By Form
      • 9.3.3.2.3. By Application

10. Middle East and Africa Losartan Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Source
  • 10.2.2. By Form
  • 10.2.3. By Application
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Losartan Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Source
      • 10.3.1.2.2. By Form
      • 10.3.1.2.3. By Application
  • 10.3.2. Saudi Arabia Losartan Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Source
      • 10.3.2.2.2. By Form
      • 10.3.2.2.3. By Application
  • 10.3.3. UAE Losartan Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Source
      • 10.3.3.2.2. By Form
      • 10.3.3.2.3. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global Losartan Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Business Overview
• 15.2. Service Offerings
• 15.3. Recent Developments
• 15.4. Key Personnel
• 15.5. SWOT Analysis
  • 15.5.1. Merck & Co. Inc.
  • 15.5.2. Pfizer Inc.
  • 15.5.3. Teva Pharmaceutical Industries Ltd.
  • 15.5.4. Sanofi S.A.
  • 15.5.5. Novartis International AG
  • 15.5.6. Dr. Reddy's Laboratories Ltd.
  • 15.5.7. Sun Pharmaceuticals Industries Ltd.
  • 15.5.8. Aurobindo Pharma Ltd.
  • 15.5.9. Torrent Pharmaceutical Ltd.
  • 15.5.10. Lupin Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer